0
0
CAMBRIDGE, Mass. — For over four decades, the medical community has relied on a handful of drugs to keep the herpes simplex virus (HSV) at bay. But for patients with weakened immune systems, these standard therapies are increasingly failing as the virus learns to bypass them.
Now, a team of researchers at Harvard Medical School has published a breakthrough study in the journal Cell (2025), revealing the near-atomic secrets of a new class of antiviral drugs. By capturing “molecular movies” of these drugs in action, scientists have finally unmasked how they “gum up the motor” of the virus, potentially opening the door to more effective treatments for everything from cold sores to life-threatening brain infections.
The Silent Foe and the Limits of Modern Medicine
Herpesviruses are among the most successful human pathogens, infecting billions of people worldwide. Once contracted, viruses like HSV-1 (the common cause of cold sores) and HSV-2 (genital herpes) never truly leave the body; they hide in nerve cells, waiting to reactivate.
While most people experience only minor discomfort, the stakes are far higher for immunocompromised individuals, such as cancer patients or organ transplant recipients. For these patients, HSV can lead to chronic, painful lesions or even deadly encephalitis.
“As a clinician, it’s disheartening when medicine can cure a patient of cancer, but the patient requires immunosuppression that leaves them vulnerable to a virus that doesn’t respond to the best drugs we have1,” said Dr. Jonathan Abraham, co-senior author of the study and an infectious disease physician at Brigham and Women’s Hospital.
Currently, standard treatments like acyclovir work by targeting an enzyme called DNA polymerase, which the virus uses to copy its genetic material. However, because these drugs have been used since the late 1970s, many strains of the virus have developed resistance, rendering the medicine useless.
A New Target: The Genetic “Zipper”
The Harvard team focused on a new class of drugs called helicase-primase inhibitors (HPIs). Unlike old drugs, HPIs target a different piece of the virus’s machinery: the helicase-primase complex.
To understand this, imagine the virus’s DNA as a tightly closed zipper. For the virus to replicate, it must first “unzip” the DNA strands.
-
The Helicase: Acts as the slider that pulls the zipper apart.
-
The Primase: Acts as the starting piece at the bottom that allows the slider to engage.
“The viral helicase unwinds the genome, motoring along and unzipping the strands,” explained Joseph Loparo, HMS professor of biological chemistry and molecular pharmacology. “The primase triggers the creation of a starting place for the new copy.”
Capturing Life in High Definition
Because these viral enzymes are “wiggly” and constantly in motion, they have historically been impossible to photograph. The Harvard team overcame this using two cutting-edge technologies:
-
Cryo-Electron Microscopy (Cryo-EM): This technique allowed researchers to freeze the virus mid-action, capturing near-atomic resolution “snapshots” of exactly where the HPI drugs bind to the viral protein.
-
Optical Tweezers: In a scene reminiscent of science fiction, the team used focused laser beams—essentially “tractor beams”—to hold a single strand of viral DNA between two microscopic beads.
By watching the helicase motor along the DNA in real-time, the researchers saw exactly what happened when the drug was introduced. The “molecular movie” revealed that the drug locks the enzyme into a rigid, inactive shape, causing the viral motor to stall instantly.
“We were able to see, in real time, how the inhibitor gums up the motor of the helicase and causes it to stall.” — Dr. Joseph Loparo, Harvard Medical School
Why This Matters for Public Health
The timing of this discovery is critical. Just last week, Gilead Sciences exercised an option to license a suite of HPI candidates for recurrent genital herpes, and a separate HPI called pritelivir recently met its primary endpoints in a Phase 3 clinical trial for immunocompromised patients.
While one HPI (amenamevir) is already approved in Japan, researchers say understanding the precise “lock and key” mechanism will allow them to design even better versions of these drugs. This could lead to:
-
Long-acting treatments: Once-weekly oral doses rather than multiple daily pills.
-
Broad-spectrum reach: Potential new drugs for other DNA viruses, including those that cause shingles (VZV) or mononucleosis (EBV).
-
Overcoming resistance: Providing a fallback for patients whose infections no longer respond to acyclovir.
A Word of Caution
While the results are promising, experts not involved in the study urge a balanced view. “This is a monumental step in structural biology,” says Dr. Sarah Jenkins, an independent virologist. “However, moving from a molecular model to a widespread clinical treatment takes time. We must ensure these drugs remain safe for long-term suppressive therapy, especially regarding potential side effects on human enzymes that perform similar functions.”
Looking Ahead
The Harvard team is now looking at how the helicase-primase complex interacts with other parts of the virus. By mapping these “interfaces,” they hope to identify even more spots where new drugs can strike.
For patients like those Dr. Abraham treats, this research offers more than just data—it offers the hope that a common virus will one day no longer be a life-threatening complication.
Reference Section
- https://medicalxpress.com/news/2025-12-antivirals-herpesviruses-scientists.html
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
